Activity Date: 10/11/2024
Registration is not configured for this course.Date: Friday, 10/11/2024
Time: 12:00 PM
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Postpartum depression (PPD) is one of the most common complications during pregnancy and a leading cause of postpartum mortality in the first year of life. While screening and diagnosis of PPD has improved in recent years, there is still an access and treatment gap for patients that needs to be addressed. Overall, there is an unmet need for fast-acting, effective pharmacotherapies for PPD to minimize the potential consequences in treatment delays. The neuroactive steroids (NAS), brexanolone and zuranolone, have a unique mechanism of action and offer rapid onset with a short treatment course. Though, where these medications fit into current practice and when/how they should be used may pose a challenge for clinicians. This program will help ensure psychiatric pharmacists and other health care professionals involved in PPD management understand the potential benefits and drawbacks to available treatments – including newer NAS medications – while considering efficacy and minimizing patient exposure to adverse events.
Lauren M. Osborne, MD
View biographical information and disclosures
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
This activity is supported by an educational grant from Sage Therapeutics, Inc. and Biogen, Inc.